Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1808 as Single Agent and in Combination With Pembrolizumab in Advanced Malignancies
NCT04752826Phase 2Recruiting
- Sponsor
- BioInvent International
- Start
- Jan 2021
- Primary completion
- Jan 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of BI-1808 in advanced cancer, ovarian cancer, T-cell lymphoma, melanoma, sponsored by BioInvent International. Started Jan 2021; status: recruiting.
02
Drugs
BI-1808
03
Conditions
advanced cancerovarian cancerT-cell lymphomamelanoma
Beyond the preview
Go deeper on NCT04752826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752826.